The adverse reaction to menin inhibitors is not limited to typical differentiation syndrome (DS) pulmonary symptoms. It presents as a broad 'menin syndrome' with diverse manifestations like bone pain, rashes, and swollen lymph nodes, requiring a new diagnostic framework for clinicians.

The differentiation syndrome (DS) from menin inhibitors is often more severe and rapid than seen with other AML drugs. It can escalate into a "crisis" with DIC and heart failure, requiring an immediate drug pause, steroids, and potentially cytoreduction.

When patients on menin inhibitors show worsening symptoms in early weeks, it's hard to distinguish disease progression from differentiation syndrome. The recommended clinical strategy is to default to treating for differentiation syndrome first, as it may be a manageable side effect rather than treatment failure.

Initial studies combining menin inhibitors with venetoclax/azacitidine showed high remission rates but also high mortality. Using each agent at its full, 28-day dose caused severe, fatal myelosuppression, forcing protocol amendments to shorten drug exposure to manage toxicity.

When an AML patient presents with multiple targetable mutations (FLT3, NPM1, IDH), clinicians follow a treatment hierarchy. FLT3-targeted therapy is typically the first choice due to its aggressive phenotype. Menin inhibitors for NPM1 are next, followed by IDH inhibitors, guiding treatment decisions in complex cases.

The differentiation syndrome with menin inhibitors can be far more severe than with other agents, manifesting as a life-threatening, HLH-like state with massive inflammatory marker elevation (e.g., ferritin >300,000) that may be unresponsive to high-dose steroids.

Combining menin inhibitors with intensive chemotherapy can decrease the risk of differentiation syndrome, a severe side effect. The chemotherapy debulks the tumor, reducing the number of malignant cells available to cause this inflammatory reaction when they differentiate, improving tolerability.

Unlike typical targeted therapies that block a mutated receptor, menin inhibitors work by disrupting a master transcription complex. This forces leukemic cells to mature (differentiate) into terminal forms like neutrophils, after which they naturally die off.

When menin inhibitors are combined with a chemotherapy backbone like induction or Aza/Ven for newly diagnosed AML, the risk of differentiation syndrome (DS) is significantly lower than when they are used as monotherapy in the relapsed setting.